Q4 revenue up 39% YoY to $11.9M; guides FY22 rev $51.4-52.2M

IRADIMED CORP

2021-FY EPS reported $0.74 revenue$41,814,581

Q4 2021 GAAP diluted EPS $0.31 vs $0.05 YoY; non-GAAP diluted EPS $0.33 vs $0.07.
Full-year 2021 revenue $41.8M (+32% YoY); full-year GAAP EPS $0.74 vs $0.11.
Gross profit margin improved to 77.9% in Q4 vs 75.3% YoY; free cash flow $10.8M for FY.
FY2022 guidance: revenue $51.4M-$52.2M, GAAP EPS $0.82-$0.90; Q1 rev $12.1M-$12.3M.
Record bookings growth: Q4 bookings +48% YoY, FY bookings +39% YoY, signaling strong demand.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.